Full-year results to 31 March were in line with the April trading update, with revenues, adjusted pre-tax loss and year-end net debt of £9.8m, £0.3m and £0.8m, respectively. A return to profitability in the second half, buoyed by a strong Food Intolerance performance and cost savings, provides a solid base from which to grow. More relevant is the update on the VISITECT CD4 Advanced Disease test, having recently received EPRD clearance and the prospect of first orders from UN
23 Sep 2019
Omega Diagnostics - Full-year results – VISITECT visibility
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Omega Diagnostics - Full-year results – VISITECT visibility
Cambridge Nutritional Sciences PLC (CNSL:LON) | 3.2 0 0.0% | Mkt Cap: 7.73m
- Published:
23 Sep 2019 -
Author:
Mark Brewer -
Pages:
17
Full-year results to 31 March were in line with the April trading update, with revenues, adjusted pre-tax loss and year-end net debt of £9.8m, £0.3m and £0.8m, respectively. A return to profitability in the second half, buoyed by a strong Food Intolerance performance and cost savings, provides a solid base from which to grow. More relevant is the update on the VISITECT CD4 Advanced Disease test, having recently received EPRD clearance and the prospect of first orders from UN